Can-Fite BioPharma
  • ABOUT
    • Overview
    • Management
    • Drug Development Team
    • Board of Directors
    • Corporate Partnerships
  • SCIENCE
    • Technology Platform
    • Scientific Publications
  • PIPELINE
    • Overview
    • Piclidenoson (CF101)
    • Namodenoson (CF102)
    • CF602
    • Cannabinoids
  • INVESTORS
    • Overview
    • News & Events
    • Company Information
    • Financial Information
    • Stock Information
    • SEC Fillings
    • Corporate Governance
    • Shareholders Meetings
  • CONTACT

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • In The News
    • Research
    • Events Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Video
    • Management
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Governance Documents
  • Shareholders Meetings
  • News & Events

  • Overview
  • Press Releases
  • In The News
  • Research
  • Events Calendar
  • Presentations
  • Email Alerts
Oct 13, 2015 8:00am EDT

Can-Fite BioPharma Announces $4.8 Million Registered Direct Offering

Oct 12, 2015 7:00am EDT

European Medicines Agency Grants Orphan Designation to Can-Fite's CF102 in the Treatment of Liver Cancer

Oct 07, 2015 7:00am EDT

Can-Fite to Deliver 2 Presentations on its Cancer Drug CF102 at the 20th World Congress on Advances in Oncology and 18th International Symposium on Molecular Medicine on October 8-10, 2015 in Athens

Sep 29, 2015 10:11am EDT

Can-Fite to Present CF101 Psoriasis Data at Late Breaking Session of the EADV Congress in Copenhagen on October 10, 2015

Sep 24, 2015 1:49pm EDT

Can-Fite BioPharma Closes $9 Million Registered Direct Offering

Sep 19, 2015 11:56pm EDT

Can-Fite BioPharma Announces $9 Million Registered Direct Offering

Sep 17, 2015 7:00am EDT

U.S. Food and Drug Administration Grants Fast Track Designation to Can-Fite's CF102 in the Treatment of Liver Cancer

Sep 01, 2015 7:00am EDT

Can-Fite to Present at Rodman & Renshaw 17th Annual Global Investment Conference on September 9, 2015

Aug 27, 2015 5:29pm EDT

Can-Fite Reports Financial Results for Six Months Ended June 30, 2015

Jul 29, 2015 7:00am EDT

World Health Organization Accepted "Piclidenoson" as Proposed New Generic Name for Can-Fite's Lead Drug Candidate CF101

  • arrow_back
  • 1
  • …
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • …
  • 45
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • HOME
  • CONTACT

© 2025 Can-Fite All Rights Reserved

BrandWiz - Branding